Online citations, reference lists, and bibliographies.
← Back to Search

Blepharospasm And Hemifacial Spasm

E. Bradley, K. Chapman, George B. Bradley
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.1212/WNL.53.3.652-A
Ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage
J. Verghese (1999)
10.1097/01.wno.0000189063.43423.04
Benign Essential Blepharospasm: Risk Factors with Reference to Hemifacial Spasm
T. A. Hall (2005)
10.1212/WNL.38.5.702
Pathology in brainstem regions of individuals with primary dystonia
R. Zweig (1988)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
10.1016/S0002-9394(14)77954-1
The use of botulinum toxin in blepharospasm.
N. Shorr (1985)
10.1007/BF00839203
The management of blepharospasm and hemifacial spasm
J. Elston (2004)
10.1212/WNL.41.11.1800
Botulinum‐induced alteration of nerve‐muscle interactions in the human orbicularis oculi following treatment for blepharospasm
K. Alderson (1991)
10.1136/jnnp.44.5.437
Brueghel's syndrome, report of a case with postmortem studies
E. García-Albea (1981)
10.1212/WNL.45.9.1743
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
10.1093/NEUROSURGERY/26.CN_SUPPL_1.607
Microsurgery of cranial nerve cross-compression.
P. Jannetta (1979)
[Clinical and therapeutic aspects of essential blepharospasm].
L. Russegger (1989)
10.1136/bmj.290.6485.1857
Effect of treatment with botulinum toxin on neurogenic blepharospasm.
J. Elston (1985)
10.1227/00006123-198308000-00006
Hemifacial spasm: treatment by microsurgical facial nerve decompression.
J. Loeser (1983)
10.1016/S0161-6420(93)31384-9
Serum antibody production to botulinum A toxin.
R. Siatkowski (1993)
10.1016/S0161-6420(86)33641-8
Treatment of facial spasm with botulinum toxin. An interim report.
B. Frueh (1986)
10.1111/j.1468-1331.2005.01095.x
The use of botulinum toxin type‐B in the treatment of patients who have become unresponsive to botulinum toxin type‐A – initial experiences
M. Barnes (2005)
10.1016/S0161-6420(97)30220-6
Blepharospasm and hemifacial spasm. Randomized trial to determine the most appropriate location for botulinum toxin injections.
J. Price (1997)
10.1136/bjo.75.8.487
Surgical management of essential blepharospasm.
A. Bates (1991)
10.1097/00002826-198610000-00002
Botulinum injection therapy for blepharospasm: a review and report of 75 patients.
D. Cohen (1986)
10.1136/jnnp.2005.068007
A family study on primary blepharospasm
G. Defazio (2006)
10.1212/WNL.55.5.673
The metabolic topography of essential blepharospasm
M. Hutchinson (2000)
10.1001/ARCHOPHT.1981.03930011056015
Blepharospasm surgery. An anatomical approach.
W. Gillum (1981)
Surgical management of blepharospasm.
R. Anderson (1988)
10.1212/WNL.47.1.43
Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm
C. E. Scheidt (1996)
10.1016/S0002-9394(03)00895-X
Positron emission tomography scanning in essential blepharospasm.
J. Kerrison (2003)
10.1097/00002341-200107000-00007
Differential Section of the Seventh Nerve as a Tertiary Procedure for the Treatment of Benign Essential Blepharospasm
R. Fante (2001)
10.1097/00004397-199103140-00011
Botulinum Toxin Injections for Treatment of Blepharospasm and Hemifacial Spasm
J. Wirtschafter (1991)
10.1002/mds.10209
Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024)
B. Racette (2002)
10.1097/00002341-199901000-00006
Positron emission tomography in patients with benign essential blepharospasm.
B. Esmaeli-Gutstein (1999)
10.1001/ARCHOPHT.1984.01040030216030
Treatment of essential blepharospasm. I. Comparison of facial nerve avulsion and eyebrow-eyelid muscle stripping procedure.
C. McCord (1984)
10.1016/J.AJO.2004.02.062
A randomized, placebo-controlled, crossover clinical trial of super blue-green algae in patients with essential blepharospasm or Meige syndrome.
S. Vitale (2004)
10.1212/WNL.34.7.891
Pathophysiology of hemifacial spasm
V. Nielsen (1984)
10.1001/ARCHOPHT.1991.01080030095046
Histologic features of human orbicularis oculi treated with botulinum A toxin.
C. P. Harris (1991)
10.1002/MDS.870130347
Blepharospasm associated with bilateral infarcts confined to the thalamus: Case report
M. Miranda (1998)
10.1016/0165-3806(94)90047-7
Botulinum A toxin stimulates neurite branching in nerve-muscle cocultures.
P. H. Bonner (1994)
10.1097/00002341-199911000-00003
A novel mechanism for benign essential blepharospasm.
J. McCann (1999)
10.1097/00007611-199103000-00019
Cerebellar degeneration and Meige's syndrome.
Khara Js (1991)
10.1001/ARCHOPHT.1990.01070080054035
Hemifacial spasm in infancy.
U. Flüeler (1990)
10.1016/J.OPHTHA.2005.06.030
Modulation of sensory photophobia in essential blepharospasm with chromatic lenses.
Natasha L Herz (2005)
10.1002/1531-8257(200101)16:1<181::AID-MDS1036>3.0.CO;2-C
Asymmetrical blepharospasm associated with a left frontal cortical infarct
G. Wali (2001)
10.1111/J.1442-9071.1994.TB00793.X
Efficacy and side effects of botulinum toxin treatment for blepharospasm and hemifacial spasm.
J. Price (1994)
10.1002/mds.20522
Meige syndrome and pallidal deep brain stimulation
Melissa Houser (2005)
10.1212/WNL.46.1.26
Botulinum toxin therapy, immunologic resistance, and problems with available materials
G. Borodic (1996)
10.1212/01.WNL.0000027361.73814.0E
Blepharospasm: recent advances.
M. Hallett (2002)
10.3109/02688699309103496
Hemifacial spasm: early postoperative normalization of blink reflex latency.
S. Sood (1993)
10.1016/S0002-9394(98)00099-3
Spontaneous remission in patients with essential blepharospasm and Meige syndrome.
A. Castelbuono (1998)
10.1016/S0161-6420(87)33337-8
Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias.
J. Mauriello (1987)
10.1016/S0161-6420(98)93484-4
Long-term efficacy of local doxorubicin chemomyectomy in patients with blepharospasm and hemifacial spasm.
J. Wirtschafter (1998)
10.1080/00016489.1985.12005666
Neurovascular decompression for hemifacial spasm.
H. Saito (1984)
10.1159/000116961
Botulinum toxin: preferred treatment for hemifacial spasm.
M. Flanders (1993)
10.1212/01.WNL.0000068527.25191.78
Bilateral pallidal stimulation for blepharospasm–oromandibular dystonia (Meige syndrome)
H. Capelle (2003)
10.1001/ARCHOPHT.1991.01080030098047
Botulinum-induced changes in monkey eyelid muscle. Comparison with changes seen in extraocular muscle.
J. Porter (1991)
10.1111/j.1600-0404.2004.00357.x
Health‐related quality of life in blepharospasm or hemifacial spasm
J. Reimer (2005)
10.1016/S0161-6420(88)33044-7
Hemifacial spasm due to intracranial tumor. An international survey of botulinum toxin investigators.
C. Sprik (1988)
10.1016/S0002-7154(67)50584-7
Differential section of the facial nerve for blepharospasm.
D. H. Reynolds (1967)
10.1016/S0161-6420(87)33458-X
Hemifacial spasm. Results of unilateral myectomy.
P. Garland (1987)
10.1097/01.IOP.0000065203.88182.CF
Benign Essential Blepharospasm Among Residents of Olmsted County, Minnesota, 1976 to 1995: An Epidemiologic Study
E. Bradley (2003)
10.1212/WNL.33.6.802
Spontaneous oral‐facial dyskinesia
P. Altrocchi (1983)
10.1016/S0002-9394(14)74794-4
Effects of eyelid protractor excision for the treatment of benign essential blepharospasm.
B. Frueh (1992)
10.1016/S0161-6420(87)33338-X
Effectiveness of botulinum toxin therapy for essential blepharospasm.
P. Engstrom (1987)
10.1016/S0025-6196(12)62028-X
Hemifacial spasm: results of microvascular decompression of the facial nerve in 54 patients.
R. Auger (1986)
10.1002/MDS.870090404
Clinical and electromyographic features of levator palpebrae superioris muscle dysfunction in involuntary eyelid closure
M. Aramideh (1994)



Semantic Scholar Logo Some data provided by SemanticScholar